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Nuclear factor of activated T cells (NFAT) is an important regulator of T cell activation. However, the
molecular mechanism whereby NFATc2 regulates IL2 transcription is not fully understood. In this
study, we showed that ubiquitin-speciﬁc protease 22 (USP22), known as a cancer stem cell marker,
speciﬁcally interacted with and deubiquitinated NFATc2. USP22 stabilized NFATc2 protein levels,
which required its deubiquitinase activity. Consistent with these observations, depletion of USP22
in T cells reduced the expression of IL2, which is a cytokine that signiﬁes T effector cell activation.
Our ﬁndings thus unveil a previously uncharacterized positive regulator of NFATc2, suggesting that
targeting the deubiquitinase activity of USP22 could have therapeutic beneﬁt to control IL2 expres-
sion and T cell function.
Structured summary of protein interactions:
NFATc2 physically interacts with USP22 by anti tag coimmunoprecipitation (1, 2)
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T cells are activated through the TCR and costimulatory path-
ways, the latter predominantly mediated by the cell surface
receptor CD28. The ligation of TCR and CD28 activates phosphory-
lation-based signaling cascades that result in the activation of
transcription factors, including nuclear factor of activated T cells
(NFAT), activator protein 1 (AP-1), and nuclear factor of kappa light
chain enhancer in B cells (NF-jB), to promote expression of
proteins that drive T cell activation, such as interleukin-2 (IL2) [1].
NFAT belongs to a transcription factor family of ﬁve members
(NFAT1 (also known as NFATp or NFATc2), NFAT2 (also known as
NFATc or NFATc1), NFAT3 (also known as NFATc4), NFAT4 (also
known as NFATx or NFATc3) and NFAT5, that all have a highly con-
served DNA binding domain [2]. In T lymphocytes, NFAT plays a
pivotal role in regulating T cell development, activation, differenti-
ation and the induction and maintenance of T cell tolerance [2].
NFAT proteins are phosphorylated and localize to the cytoplasm
in resting cells. The increase in intracellular calcium concentration
induces activation of the calcineurin phosphatase complex, whichdephosphorylates NFAT and leads to its translocation into the nu-
cleus for the induction of target gene transcription [3]. Leucine-rich
repeat kinase 2 (LRRK2) affects the cytoplasmic sequestration of
NFAT1 but not its phosphorylation, and inhibits the function of
NFAT1 in the nucleus. LRRK2-deﬁcient mice suffer severe colitis,
which is due to the enhanced nuclear localization of NFAT1 [4].
E26 transformation-speciﬁc sequence 1 (Ets-1) was recently found
to physically and functionally interact with NFATc2. Ets-1 exits the
nucleus in response to calcium-dependent signaling, and facilitates
NFATc2 nuclear localization and recruitment to the IL2 promoter
[5]. In breast and pancreatic cancer cells, GSK3b stabilizes nuclear
NFATc2 through phosphorylation of the serine-rich SP2 domain,
thus protecting NFATc2 from E3-ubiquitin ligase HDM2-mediated
proteolysis [6]. However, it is still unclear as to the molecular
mechanism of how ubiquitination and deubiquitination regulate
NFATc2 stability and function.
Ubiquitin-speciﬁc proteases (USPs) are a large family of pro-
teins, and their functions in T cell immunity have just begun to
be studied and appreciated [7–10]. Ubiquitin-speciﬁc protease 22
(USP22) was ﬁrst identiﬁed as a subunit of the human SAGA com-
plex (hSAGA), a multiprotein transcriptional cofactor complex
broadly required for the function of sequence-speciﬁc transcription
activators in eukaryotes [11]. USP22 has been reported to have
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moieties from its substrates [12]. USP22 is widely expressed in dif-
ferent human tissues suggesting that it functions ubiquitously [12].
USP22 can deubiquitinate histone H2B and is required for the
activation of target gene transcription by Myc [11]. USP22 can also
regulate cell proliferation and tumorigenesis by deubiquitinating
far upstream element (FUSE)-binding protein 1 (FBP1) [13].
Ablation of USP22 does not affect the protein stability of FBP1
but increases ubiquitination of FBP1 and decreases FBP1 occupancy
at the p21 gene [13]. USP22 also deubiquitinates Sirt1, a
NAD-dependent histone deacetylase, which antagonizes p53 tran-
scriptional activity to regulate cell-cycle progression and apoptosis
[14]. Despite the many reports that have studied the function of
USP22 in cell-cycle progression, apoptosis and tumorigenesis, the
function of USP22 in the immune system remains largely unclear.
It has been demonstrated that USP22 interacts with Sirt1 and
removes Sirt1 polyubiquitination to enhance its protein stability
[14]. Sirt1 was also found to interact with and deacetylate c-Jun,
yielding an inactive AP-1 factor, thus negatively regulating T cell
activation [15]. Therefore, we hypothesized that USP22 may have
a function in T cell activation. In this study, we have characterized
the role of USP22 in T cells. We found that USP22 depletion in Jur-
kat T cells impaired T cell activation and IL2 expression after TCR
stimulation. We found that USP22 could physically interact with
and stabilize NFATc2 by deubiquitination. Our results thus reveal
a novel role of USP22 in controlling the T cell immune response
by serving as a positive regulator of NFATc2.
2. Materials and methods
2.1. Plasmids, antibodies and reagents
NFATc2 and USP22 were ampliﬁed from human PBMC cDNA,
and then cloned into the pIRES2-puro vector with different tags.
The shRNA expression vector pLKO.1 was purchased from Add-
gene. Flag-USP22RE plasmid was generated by site-directed muta-
genesis with six silent mutations in the USP22 region targeted by
the shUSP22-1. The plasmids FUGW, del8.9 and VSV-G were gifts
from Ke Lan (Institut Pasteur of Shanghai, CAS). The antibodies
used in this study were as follows: anti-NFATc2 (4G6-G5, Santa
Cruz Biotechnology), anti-USP22 (N3C3, Genetex), anti-Ub (P4D1,
Santa Cruz Biotechnology), anti-HA (F-7, Santa Cruz Biotechnol-
ogy), anti-Myc (9E10, Santa Cruz Biotechnology), anti-Flag (M2,
Sigma–Aldrich), anti-b-actin (Sigma–Aldrich). Protein A/G PLUS
Agarose (sc-2003) was purchased from Santa Cruz Biotechnology.
MG132 (CAS 133407-82-6) was from Merck.
2.2. Cell culture and transfection
HEK 293T cells were cultured in Dulbecco Modiﬁed Eagle med-
ium (DMEM) containing 10% heat-inactivated fetal bovine serum
(FBS) and transfected using PEI (Polysciences) according to the
manufacturer’s instructions. Jurkat cells were maintained in RPMI
1640 medium containing 10% FBS, 1% penicillin/streptomycin, 1%
sodium pyruvate, 1% non-essential amino acids and 1% L-gluta-
mine. Jurkat cells were activated by treating with phorbol 12-myr-
istate 13-acetate (PMA) (50 ng/ml) plus ionomycin (1 lM).
2.3. Immunoprecipitation and immunoblotting
Cells were harvested and washed with ice-cold PBS and lysed
on ice for 30 min in RIPA buffer (50 mM Tris–HCl, pH 7.5;
150 mM NaCl; 1% NP-40; 0.25% NaDoc; 1 mMMgCl2; 10% glycerol)
containing protease inhibitor (1:100, P8340, Sigma–Aldrich), NaF
(10 mM), PMSF (1 mM) and Na3VO4(1 mM). Cell lysates werecleared by centrifugation and supernatants were immunoprecipi-
tated with the appropriate antibodies for 1 h at 4 C and then with
protein A/G PLUS Agarose for another 1 h at 4 C. The immunocom-
plexes were then washed with RIPA buffer 4 times and examined
by Western blotting by standard procedures.
2.4. Ubiquitin pull-down assay
Ubiquitin pull down assay was performed as described [9]. In
brief, cells transfected with His-tagged ubiquitin and Myc-tagged
NFATc2 or HA-tagged USP22 were treated with 20 lM MG132
4 h before harvesting. Cells were washed with ice-cold PBS, then
lysed in urea buffer (8 M urea, 100 mM Na2HPO4, 10 mM Tris [pH
8.0], 0.2% Triton X-100, 10 mM imidazole) and incubated with
Ni–NTA beads for 2 h at room temperature. The beads were
washed twice in pH 8 urea buffer, twice in pH 6.3 urea
buffer (8 M urea, 100 mM Na2HPO4, 10 mM Tris [pH 6.3], 0.2%
Triton X-100, 10 mM imidazole), and once in a wash buffer
(20 mM Tris [pH 8.0], 100 mM NaCl, 20% glycerol, 10 mM
imidazole). Beads were boiled in 2X loading buffer and analyzed
by SDS–PAGE.
2.5. Luciferase reporter assay
The 1000-bp region upstream of the human IL2 transcriptional
starting site (Location: Chromosome 4: 123,372,625-123,377,880)
was cloned into the pGL3-Basic vector to generate the pGL3-IL2-
luc reporter construct. For the luciferase assay, pGL3-IL2-luc was
electroporated with the plasmids as indicated and an internal
control plasmid expressed Renilla luciferase into Jurkat cells.
3 days after transfection, cells were washed with PBS and
lysed in luciferase lysis buffer. The ﬁreﬂy luciferase and Renilla
luciferase were performed using the Dual-luciferase reporter kit
(Promega).
2.6. Viral transduction
The plasmids pLKO.1-shCK or pLKO.1-shUSP22 were co-trans-
fected with del8.9 and VSV-G into HEK293T cells by calcium-
phosphate transfection. 2 days after transfection, the viral
supernatants were harvested. Jurkat cells were incubated with
viral supernatants containing 8 lg/ml polybrene overnight. After
removal of the viral supernatants, cells were cultured with fresh
medium. 2 days post-transduction, puromycin was added to select
for stable cell lines. The shRNA target sequences used were as
follows:
50-CAACAAGATGAAGAGCACCAA-30 (shCK);
50-CGAAGGGTACTTGCTGTTCTA-30 (shUSP22-1);
50-AGCTACCAGGAGTCCACAAAG-30 (shUSP22-2).
2.7. RNA extraction, reverse transcription and quantitative PCR
Total RNA was extracted using TRIzol reagent (Invitrogen).
cDNA was synthesized using a reverse transcriptase kit (TaKaRa)
following the manufacturer’s instructions. mRNA levels were
assessed relative to HPRT mRNA levels using SYBR green (TaKaRa)
on an ABI Prism 7500 system. The following primers were used
for RT-qPCR: IL2 forward, 50-CCCAGGGACTTAATCAGCAA-30 and
reverse, 50-GCCTGATATGTTTTAAGTGGAAG-30; USP22 forward,
50-ATATTCACGAGCATGCGAAG-30 and reverse, 50-GGTTGGTTCCC
AAGTTGAAA-30; NFATc1 forward, 50-CCTCCAACCCCATCGAATG-30
and reverse, 50-TTTTCGCTTCCATCTCCCAG-30; NFATc2 forward,
50-CCACTATGAGACAGAAGGCAG-30 and reverse, 50-TGACAGTTTTCC
CCGTGATTC-30; HPRT forward, 50-GCTATAAATTCTTTGCTGACCT
GCTG-30 and reverse, 50-AATTACTTTTATGTCCCCTGTTGACTGG-30.
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3.1. USP22 depletion attenuates IL2 expression in Jurkat cells upon
activation
To evaluate the role of USP22 in T cell function, we depleted
USP22 in Jurkat cells by lentivirus-mediated shRNA transduction.
We found that USP22-depleted Jurkat cells (shUSP22-1) produced
less IL2 compared with control cells (shCK) after PMA and ionomy-
cin stimulation (Fig. 1A and B). The Western blotting showed that
USP22 protein expression was depleted in USP22 knockdown Jur-
kat cells (Fig. 1C). To exclude the off-target effect of shRNA, we also
tested another shRNA (shUSP22-2), which targeted a different se-
quence within the USP22 CDS and the results were consistent with
what was obtained using shUSP22-1 (Supplementary Fig. 1A–C).
Taken together, these data suggest that USP22 positively regulates
TCR-induced T cell activation by restricting IL2 production.
3.2. USP22 interacts with NFATc2
To investigate how USP22 upregulates IL2 expression, we
hypothesized that USP22 may cooperate with some transcription
factors to regulate IL2 expression. It has been identiﬁed that a con-
sensus transcription factor binding site for NFAT exists on the up-
stream promoter region of IL2 [16–19]. We then examined the
interaction between USP22 and NFATc2. HEK293T cells were co-
transfected with tagged USP22 and/or NFATc2 expression con-
structs for co-immunoprecipitation analysis. NFATc2 and USP22
were found able to interact in reciprocal fashion (Fig. 2A and B).
As NFATc1 has high homology with NFATc2, we also tested the
interaction between USP22 and NFATc1. The reciprocal co-immu-
noprecipitation assay showed that USP22 could not interact with
NFATc1 (Fig. 2C and D). Collectively these results indicated that
USP22 can interact with NFATc2.
3.3. USP22 deubiquitinates NFATc2
Because the deubiquitinase USP22 interacts with NFATc2, we
hypothesized that USP22 might facilitate NFATc2 deubiquitination.
We co-transfected NFATc2 and USP22 with Flag-tagged ubiquitin
into HEK293T cells. 2 days after transfection, cells were treated
with the proteasome inhibitor MG132 to stabilize the ubiquitinat-
ed proteins followed byWestern blotting. We found that wild-type
USP22 but not the catalytically inactive mutant USP22C185A de-
creased the ubiquitination level of NFATc2 (Fig. 3A).
To exclude the possibility that the ubiquitin bands were from
other NFATc2 binding proteins but not NFATc2 itself, His-tagged
ubiquitin (His-Ubi) was overexpressed with wild-type USP22 or
the catalytically inactive mutant USP22C185A in HEK293T cells,Fig. 1. USP22 depletion attenuates IL2 transcription in Jurkat cells upon activation st
sequences control (shCK) or targeting USP22 (shUSP22-1). 4 days post-transduction, c
indicated time periods. Total RNA was extracted, and the mRNA levels of IL2 (A) and US
value of shCK at 0 h by RT-qPCR. (C) Cell lysates from Jurkat (shCK) and Jurkat (shUSP22
blotting.and Ni–NTA pull-down was performed in denaturing conditions
(Fig. 3B). The level of ubiquitinated NFATc2 was signiﬁcantly re-
duced in the presence of wild-type USP22 but not its mutant
USP22C185A. Furthermore, we co-transfected HA-tagged NFATc2
with Flag-tagged USP22 or USP22C185A into HEK293T cells. Co-
immunoprecipitation was performed and endogenous ubiquitin
was detected by Western blotting (Fig. 3C). Consistent with previ-
ous results, overexpression of USP22 but not the USP22C185A mu-
tant could reduce ubiquitination of NFATc2. We then tested
whether the USP22C185Amutant might impair its interaction with
NFATc2 by co-immunoprecipitation. Our results show that both
wild-type USP22 and USP22C185A could interact with NFATc2
similarly (Fig. 3D). Thus, our data indicated that USP22 deubiquiti-
nates NFATc2, which requires its enzymatic activity.
3.4. USP22 stabilizes NFATc2
Since we found that USP22 deubiquitinates NFATc2, we rea-
soned that USP22 might control NFATc2 stability. To test this, we
monitored NFATc2 protein levels in the presence of increasing
doses of USP22 or its catalytically inactive mutant USP22C185A.
We found that USP22 stabilized NFATc2 in a dose dependent man-
ner, while the USP22C185A mutant could not (Fig. 4A). We also
found that NFATc2 protein was decreased in USP22 knockdown
cells but could be rescued by overexpression of the shUSP22-1
resistant mutant USP22-RE (Fig. 4B). In order to test whether
USP22 could affect the stability of endogenous NFATc2 protein sta-
bility in T cells, we constructed Jurkat cells stably expressing Flag
tag or Flag-tagged USP22. We found that transduction efﬁciencies
were more than 95% and comparable between Jurkat (Flag) and
Jurkat (Flag-USP22) cells (Fig. 4C). USP22 expression was also con-
ﬁrmed by Western blotting (Fig. 4D) and RT-qPCR (Fig. 4E). More-
over, both cells expressed similar mRNA levels of NFATc1 and
NFATc2 (Fig. 4F and G). The endogenous NFATc2 protein level
was higher in Jurkat (Flag-USP22) cells and Jurkat (Flag) cells trea-
ted with MG132 than Jurkat (Flag) cells (Fig. 4H). Collectively, our
results suggested that the stability of NFATc2 is controlled by pro-
teasome-mediated degradation and USP22 enhanced NFATc2 pro-
tein stability by decreasing its ubiquitination.
3.5. Knockdown of USP22 inhibits IL2 transcription through controlling
NFATc2 stability
As our previous results showed that USP22 regulates NFATc2
protein stability, we next determined whether USP22 is involved
in regulation of NFATc2 function. We electroporated Jurkat cells
with IL2-luciferase plasmids together with shUSP22-1 and indi-
cated plasmids, and stimulated cells with PMA and ionomycin
(Fig. 5A). We found that IL2-luciferase was reduced in USP22imulus. (A and B) Jurkat cells were transduced with lentivirus containing shRNA
ells were stimulated with or without 50 ng/ml PMA and 1 lM ionomycin for the
P22 (B) were assessed relative to HPRT mRNA levels and normalized against the Ct
-1) were detected with anti-USP22 antibody and anti-b-actin antibody by Western
Fig. 2. USP22 interacts with NFATc2. (A and B) Myc-NFATc2 and HA-USP22 were cotransfected into HEK293T cells. Cell lysates were immunoprecipitated with either anti-
Myc or anti-HA antibody and detected by Western blotting as indicated. (C and D) Myc-NFATc1 or Myc-NFATc2 was cotransfected with HA-USP22 into HEK293T cells. Cell
lysates were immunoprecipitated with either anti-Myc or anti-HA antibody and detected by Western blotting as indicated.
Fig. 3. USP22 deubiquitinates NFATc2. (A) Myc-NFATc2, Flag-Ubi and HA-USP22 or HA-USP22C185A were cotransfected into HEK293T cells. Cells were treated with 20 lM
MG132 4 h before harvesting. Cell lysates were immunoprecipitated with anti-Myc antibody and detected byWestern blotting as indicated. (B) Myc-NFATc2, His-Ubi and HA-
USP22 or HA-USP22C185A were cotransfected into HEK293T cells. Cells were treated with 20 lMMG132 4 h before harvesting. Cells were lysed in the buffer containing 8 M
Urea, and ubiquitinated NFATc2 was pulled down by Ni–NTA agarose. Protein blots were probed with antibodies as indicated. (C) HA-NFATc2, Flag-USP22 or Flag-
USP22C185A were cotransfected into HEK293T cells. Cells were treated with 20 lM MG132 4 h before harvesting. Cell lysates were immunoprecipitated with anti-HA
antibody and detected by Western blotting as indicated. The protein marker was shown in the left. (D) Myc-NFATc2 was cotransfected with HA-USP22 or HA-USP22C185A.
Cell lysates were immunoprecipitated with anti-Myc antibody and detected by Western blotting as indicated.
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IL2-luciferase activity indicating that downregulation of IL2-lucif-
erase in Jurkat cells was due to the knockdown of USP22. To inves-
tigate if the effect of USP22 downregulation on IL2-luciferase
activity is mediated through regulation of NFATc2 protein stability
rather than its general effect to regulate gene transcription byhistone modiﬁcation [11], we found that ectopically expressed
NFATc2 in USP22 knockdown Jurkat cells was able to rescue both
IL2-luciferase activity (Fig. 5A) and endogenous IL2 mRNA levels
(Fig. 5B and C). These results indicated that USP22 is required for
the upregulation of IL2 transcription upon T cell activation by
controlling NFATc2 protein stability.
Fig. 4. USP22 stabilizes NFATc2. (A) Myc-NFATc2 was cotransfected into HEK293T cells with increasing amounts of HA-USP22 or HA-USP22C185A plasmids. Protein blots
were probed with antibodies as indicated. (B) HEK293T cells were transfected with shCK, shUSP22-1 or shUSP22-2. 3 days after transfection, cells were cotransfected with
Myc-NFATc2 or shUSP22-1 resistant mutant Flag-USP22RE. 2 days later, cells were harvested and detected by Western blotting as indicated. (C–G) Jurkat cells were
transduced with lentivirus expressing FUGW (Flag-IRES-EGFP) or FUGW (Flag-USP22-IRES-EGFP) plasmids. GFP signals indicated transduction efﬁciency. (C) Flow cytometry
analysis of GFP expression of Jurkat (Flag) and Jurkat (Flag-USP22) cells. Jurkat cells were used as a negative control. (D) Western blotting analysis on USP22 expression in
Jurkat (Flag) and Jurkat (Flag-USP22) cells using actin as a loading control. (E–G) RT-qPCR analysis on USP22 (E), NFATc1 (F) and NFATc2 (G) mRNA levels in Jurkat (Flag) and
Jurkat (Flag-USP22) cells. Relative mRNA levels were assessed relative to HPRT mRNA levels, and then normalized against the values of Jurkat (Flag). (H) Jurkat (Flag) cells
were treated with or without 10 lMMG132 4 h before harvesting. Jurkat (Flag) and Jurkat (Flag-USP22) cells lysates were quantiﬁed by the Bradford assay. Protein blots were
probed with antibodies as indicated. Numbers under the NFATc2 bands represent their relative density.
Fig. 5. Knockdown of USP22 inhibits NFATc2-mediated activation of the IL2 transcription. (A) Jurkat cells were electroporated with IL2-luciferase plasmid and indicated
plasmids. 3 days after electroporation, cells were treated with PMA and ionomycin 4 h before harvesting. IL2-luciferase activity was ﬁrst normalized against Renilla-luciferase
activity and then against the normalized value of IL2-luc-transfected control cells. (B) Jurkat cells were electroporated with shCK or shUSP22-1 with or without Flag-tagged
NFATc2. 3 days after electroporation, cells were treated with DMSO or PMA plus ionomycin 4 h before harvesting. mRNA levels of IL2 and USP22 were assessed relative to
HPRTmRNA levels and then against the normalized values of shCK by RT-qPCR. (C) The cell lysates from B were quantitated by Bradford assay, and NFATc2 and USP22 protein
amounts were detected by Western blotting as indicated.
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IL2 plays a critical role in adaptive immune responses. NFAT
was initially identiﬁed as an inducible nuclear factor that could
bind the IL2 promoter in activated T cells [20]. However, the molec-
ular mechanism whereby NFAT dynamically and tightly regulates
IL2 transcription is still not fully understood. It has been shown
that deubiquitinases (DUBs) play critical roles in innate and adap-
tive immune responses [7–9,21]. In this study, we found that an
ubiquitin-speciﬁc protease, USP22, interacts with and deubiquiti-
nates NFATc2. Furthermore, we showed that USP22 stabilizesNFATc2 protein and promotes NFATc2 function to facilitate IL2
expression in T cells.
Previous studies reported that USP22 regulates gene transcrip-
tion in a stabilization independent manner, such that USP22 re-
moves monoubiquitin from histone H2B and H2A [11,22,23], and
K63-ubiquitin chains from FBP1 [13]. Meanwhile, USP22 may also
antagonize p53 transcriptional activation by deubiquitinating and
stabilizing Sirt1 [14]. Here, we found that USP22 could interact
and control the stability of NFATc2 by deubiquitination. NFATc2
protein became more stable in USP22 overexpressing cells
(Fig. 4A and H), while NFATc2 protein was downregulated in
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could rescue NFATc2 protein in USP22 knockdown cells (Fig. 4B)
and also restore IL2-luciferase (Fig. 5A), suggesting that USP22 is
able to stabilize NFATc2 protein and regulate its function.
Furthermore, ectopic expression of NFATc2 in USP22 knockdown
Jurkat cells could restore both IL2-luciferase activity (Fig. 5A)
and IL2 mRNA level (Fig. 5B), indicating that the effect of
USP22 on IL2 transcription is mediated through NFATc2 protein
stability but not through histone modiﬁcation. Thus, our results
indicate that USP22 may function as a positive regulator of T cell
activation.
A recent study reported that IL2 signaling suppresses Sirt1 tran-
scription by sequestering FoxO3a in the cytoplasm through the
PI3K-AKT pathway for reversal of T cell tolerance [24]. Our ﬁnding
that USP22 modulates NFATc2 function to promote IL2 production
suggests that USP22 may contribute to T cell activation by antago-
nizing Sirt1-mediated T cell anergy. However, the signals and the
molecular switch between T cell activation and T cell tolerance
and the role of USP22 in this context still needs to be further
studied.
In summary, our results reveal a crucial function of USP22 in T
cell activation and evidence for USP22 regulation of NFAT protein
stability. It is interesting that NFAT also plays an important role
in ﬁbroblast proliferation and survival, epithelial tumor cell inva-
sive migration and endothelial cell angiogenesis [25]. Our study
not only advances our understanding of the dynamic regulation
of T cell function by deubiquitination but may also provide new
therapeutic targets toward cancer therapy.
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